Catalyst Pharmaceuticals (CPRX) Competitors $20.55 +0.02 (+0.10%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$20.72 +0.17 (+0.83%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CPRX vs. ELAN, VRNA, RVMD, RGC, ABVX, MRUS, RNA, CYTK, RYTM, and GRFSShould you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Abivax (ABVX), Merus (MRUS), Avidity Biosciences (RNA), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Catalyst Pharmaceuticals vs. Its Competitors Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Regencell Bioscience Abivax Merus Avidity Biosciences Cytokinetics Rhythm Pharmaceuticals Grifols Catalyst Pharmaceuticals (NASDAQ:CPRX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Do analysts rate CPRX or ELAN? Catalyst Pharmaceuticals currently has a consensus target price of $33.20, suggesting a potential upside of 61.56%. Elanco Animal Health has a consensus target price of $19.14, suggesting a potential downside of 10.65%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Pharmaceuticals is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalyst Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00Elanco Animal Health 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91 Does the media favor CPRX or ELAN? In the previous week, Elanco Animal Health had 8 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 9 mentions for Elanco Animal Health and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.17 beat Elanco Animal Health's score of 0.64 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of CPRX or ELAN? 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CPRX or ELAN more profitable? Catalyst Pharmaceuticals has a net margin of 37.36% compared to Elanco Animal Health's net margin of 9.68%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Elanco Animal Health's return on equity.Company Net Margins Return on Equity Return on Assets Catalyst Pharmaceuticals37.36% 40.78% 35.36% Elanco Animal Health 9.68%7.04%3.45% Which has more volatility and risk, CPRX or ELAN? Catalyst Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Which has stronger earnings and valuation, CPRX or ELAN? Elanco Animal Health has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalyst Pharmaceuticals$558.50M4.50$163.89M$1.6512.45Elanco Animal Health$4.44B2.40$338M$0.8624.91 SummaryCatalyst Pharmaceuticals beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks. Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPRX vs. The Competition Export to ExcelMetricCatalyst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.52B$2.97B$6.20B$10.55BDividend YieldN/A54.19%5.70%4.81%P/E Ratio12.4523.3185.7027.13Price / Sales4.50764.66614.88134.09Price / Cash8.40169.4137.1060.81Price / Book3.375.3212.236.52Net Income$163.89M$33.06M$3.33B$276.93M7 Day Performance0.93%2.29%1.17%1.93%1 Month Performance3.89%7.35%6.85%2.19%1 Year Performance-3.25%-5.13%58.93%34.62% Catalyst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPRXCatalyst Pharmaceuticals4.8287 of 5 stars$20.55+0.1%$33.20+61.6%-3.2%$2.52B$558.50M12.4580Positive NewsELANElanco Animal Health2.576 of 5 stars$20.04+1.4%$19.14-4.5%+65.2%$9.96B$4.48B23.309,000News CoverageAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5463 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.412 of 5 stars$48.75+1.1%$74.64+53.1%+7.3%$9.11BN/A-10.83250News CoverageAnalyst ForecastInsider TradeGap UpRGCRegencell Bioscience0.3975 of 5 stars$17.99+7.0%N/AN/A$8.90BN/A0.0010News CoverageABVXAbivax3.4891 of 5 stars$95.63+2.0%$114.25+19.5%+787.4%$7.23BN/A0.0061Short Interest ↓MRUSMerus1.3934 of 5 stars$94.85+0.5%$93.12-1.8%+80.1%$7.17B$56.23M-17.2537Short Interest ↓RNAAvidity Biosciences2.548 of 5 stars$48.96-1.6%$68.32+39.5%-5.1%$7.14B$10.90M-13.75190News CoverageInsider TradeCYTKCytokinetics3.8465 of 5 stars$59.59-0.7%$76.64+28.6%+6.3%$7.13B$85.74M-11.68250Trending NewsInsider TradeRYTMRhythm Pharmaceuticals2.8746 of 5 stars$100.770.0%$106.64+5.8%+116.9%$6.69B$156.29M-33.48140News CoverageAnalyst ForecastGRFSGrifols3.7488 of 5 stars$9.45+1.4%$10.30+9.0%+11.6%$6.50B$7.81B8.0823,822 Related Companies and Tools Related Companies ELAN Alternatives VRNA Alternatives RVMD Alternatives RGC Alternatives ABVX Alternatives MRUS Alternatives RNA Alternatives CYTK Alternatives RYTM Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPRX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.